Topic: How To Invest

What is Pat’s commentary for the week of August 25, 2020

Article Excerpt

We go back a long way with medical-device supplier Baxter International. The stock is up a whopping 674.9% since we recommended it at $16.75 a share (adjusted for two 2-for-1 share splits) in our December 1999 inaugural issue of Wall Street Stock Forecaster. That gain doesn’t even include the dividend payments made over those years. It does, however, factor in the $45.47 per share that shareholders received when Ireland’s Shire plc bought Baxter’s spinoff company Baxalta in 2016 (more on that below). Baxter had spun off Baxalta a year earlier before handing its investors shares in the company. More recently, Baxter’s sales and earnings have suffered due to COVID-19. However, it’s now developing new COVID-related products, which add to the company’s already-solid prospects. I asked our Successful Investor research department to draw up this Inner Circle Spotlight report on Baxter. It explains why we think the stock remains a high-quality buy for our members. INNER CIRCLE SPOTLIGHT REPORT ON BAXTER INTERNATIONAL: This device…